GET DAILY SIGNALSAssembly Biosciences (ASMB): Can the Stock Deliver +135% Upside to Analyst Targets?
Key Takeaways
- The central target of $51 is the arithmetic mean of five verified analyst price targets, which range from $43 to $62.
- At a recent price near $21.75, reaching $51 would require upside of roughly 135% — a very large move that implies more than a doubling of the stock.
- The analyst consensus is a Strong Buy, with every reviewed rating a Buy; the wide $43-to-$62 range signals meaningful disagreement about how much the pipeline is worth.
- Supporting factors include a diversified antiviral pipeline, a collaboration with Gilead Sciences (GILD), and a cash balance of roughly $320 million.
- The biggest risks are clinical-stage execution, declining collaboration revenue, ongoing cash burn, and a stock already down about 40% year to date.
- You can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For AI-driven trading ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
The $51 central target is calculated from five current analyst price targets: $43 (Guggenheim), $48 (UBS), $50 (H.C. Wainwright), $53 (Mizuho), and $62 (Jefferies). The arithmetic mean of these figures is $51.2, rounded to $51. The range is unusually wide, spanning roughly $19 from the low to the high.
All five firms rate the stock a Buy or equivalent, which is why aggregators describe the consensus as "Strong Buy." Yet the targets reflect different assumptions. Mizuho raised its target to $53 in late August 2026, while UBS initiated coverage at $52 in September 2026 before trimming to $48 in early November. H.C. Wainwright has reiterated a $50 target, and Guggenheim raised its view to $43 in April 2026. Jefferies' $62 target dates to late 2025 and has not been updated recently, contributing to the spread. The gap between $43 and $62 shows that even bullish analysts disagree on how much value to assign to Assembly Biosciences (ASMB)'s early-stage programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $21.75, moving to $51 represents a gain of approximately 135%, a very large required move. The stock trades well below its 52-week range of about $19.20 to $39.71 and has shed roughly 40% year to date. Reaching $51 would require not only a recovery to the prior highs but a breakout to new territory.
Assembly Biosciences (ASMB) generates most of its revenue from its Gilead Sciences (GILD) collaboration, and reported revenue of about $74.8 million over the trailing twelve months against a market value near $415 million. The path toward higher levels depends primarily on clinical data readouts across its helicase-primase inhibitor, hepatitis B, and hepatitis delta programs, rather than near-term earnings.
What Could Support a Move Toward the Target
Several factors underpin the bullish view. The pipeline spans multiple viral diseases — including recurrent genital herpes, chronic hepatitis B, and hepatitis delta — reducing reliance on any single program. The Gilead Sciences (GILD) collaboration provides milestone and royalty potential and validates the science. A cash position near $320 million, supported by a recent equity raise, funds development without immediate financing pressure. Analysts' willingness to maintain Buy ratings and targets two to three times the current price reflects a view that the market is discounting the pipeline heavily. Positive Phase 1 or Phase 2 data, or an expanded collaboration, could re-rate the shares.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Assembly Biosciences (ASMB) is clinical-stage with no approved product, and consensus forecasts point to declining collaboration revenue. The company continues to burn cash, with negative free cash flow and a thin profit profile. A failed or delayed trial, an unfavorable safety signal, or a slowdown in the Gilead Sciences (GILD) relationship could compress valuation further. The stock's own chart shows investors have been selling into rallies, and the wide analyst range itself signals that the $62 high may reflect an outlier rather than a consensus view. Reaching $51 would require sustained clinical success, not merely a sentiment rebound.
Technical Levels and Market Structure
The stock's 52-week low near $19.20 acts as the nearest meaningful support level, and a break below it would mark a new multi-year low. On the upside, the prior peak near $39.71 and the psychological $40 area represent major resistance; the shares would need to clear both before the $51 target becomes technically reachable. Assembly Biosciences (ASMB) trades below both its 20-day and 200-day moving averages, indicating a downtrend that has yet to reverse. From what I see, the technical setup warrants close monitoring.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though the exact horizon varies by firm and report. Key upcoming items include the company's next earnings report, scheduled for mid-November 2026, along with clinical data updates across the herpes, hepatitis B, and hepatitis delta programs. Investors should also watch analyst target revisions, any changes to the Gilead Sciences (GILD) collaboration, cash runway updates, and sector-wide sentiment toward small-cap biotech.
Using AI Daily Buy/Sell Signals in Practice
Tickeron's AI Daily Buy/Sell Signals have become a regular part of my routine for names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from market conditions, technical behavior, and AI analysis. For a volatile clinical-stage name, these signals help highlight momentum shifts and support more disciplined risk management alongside traditional research.
Final Assessment
Can Assembly Biosciences (ASMB) reach $51? The central target — the mean of five analyst price targets spanning $43 to $62 — sits roughly 135% above the current price, making it a very ambitious objective that would require a breakout well beyond the stock's prior highs. The bull case rests on a diversified pipeline, the Gilead Sciences (GILD) partnership, and a solid cash cushion; the bear case rests on clinical-stage risk, declining revenue, and persistent cash burn. With every covering analyst holding a Buy rating but disagreeing sharply on the magnitude of upside, the target reflects genuine uncertainty. Investors should focus on clinical data, the November earnings report, and cash runway as the clearest signals of whether such a move is plausible.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ASMB sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ASMB moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ASMB entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ASMB's RSI Indicator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 56 cases where ASMB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ASMB as a result. In 75 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ASMB just turned positive on October 20, 2026. Looking at past instances where ASMB's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASMB advanced for three days, in 215 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ASMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. ASMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.360) is normal, around the industry mean (3.498). P/E Ratio (16.468) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.568) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of phamaceutical products
Industry Biotechnology
Advertisement